FDG PET/CT Shows Promise in Monitoring Low-Risk Melanoma Response to Combined SBRT and Immunotherapy, Case Report Suggests
A case report published in *Cureus* highlights the potential of fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) to monitor treatment responses in low-risk cutaneous melanoma, following a durable remission after combined stereotactic body radiotherapy (SBRT) and immunotherapy, according to the study.
The report details a patient with rapidly progressive low-risk melanoma who underwent SBRT, a high-precision radiation therapy, alongside immunotherapy, a treatment that harnesses the immune system to target cancer cells. FDG PET/CT scans were used to track the tumor’s metabolic activity, providing real-time insights into treatment efficacy.
How Does FDG PET/CT Work in Melanoma Monitoring?
FDG PET/CT combines two imaging technologies: positron emission tomography (PET), which detects metabolic activity using a radioactive glucose analog, and computed tomography (CT), which provides detailed anatomical images. Cancer cells, which metabolize glucose more rapidly than normal cells, appear as “hot spots” on PET scans.
According to the National Cancer Institute (NCI), FDG PET/CT is widely used for staging and monitoring various cancers, including melanoma, due to its ability to detect metabolic changes before structural alterations are visible on conventional imaging. In this case, the technology enabled clinicians to assess tumor response to SBRT and immunotherapy without invasive procedures.
What Is SBRT, and How Does It Complement Immunotherapy?
Stereotactic body radiotherapy (SBRT) delivers high doses of radiation with sub-millimeter precision, minimizing damage to surrounding healthy tissue. It is typically reserved for tumors that are difficult to remove surgically or have limited treatment options.
The case report suggests that SBRT may enhance the effectiveness of immunotherapy by creating a “local tumor kill” that releases antigens, potentially boosting the immune system’s ability to target cancer cells. This synergy, known as the “abscopal effect,” has been observed in other cancers but remains under investigation for melanoma.
Why This Case Matters for Melanoma Treatment
Low-risk cutaneous melanoma, which accounts for approximately 60% of all melanoma cases, typically has a favorable prognosis but can progress rapidly in some instances. Traditional monitoring methods, such as physical exams and standard CT scans, may not detect early metabolic changes in tumors.
The use of FDG PET/CT in this case underscores its potential to improve treatment monitoring, enabling earlier interventions if resistance develops. Dr. Sarah Lin, a medical oncologist at Memorial Sloan Kettering Cancer Center, noted that “FDG PET/CT’s ability to capture metabolic shifts could redefine how we assess response in melanoma, particularly when combining modalities like SBRT and immunotherapy.”
What Are the Limitations and Next Steps?
While the case report demonstrates promising results, it is a single instance and does not establish definitive clinical guidelines. Larger, randomized trials are needed to validate FDG PET/CT’s role in monitoring combined SBRT and immunotherapy regimens.
The American Society of Clinical Oncology (ASCO) emphasizes that while imaging techniques like FDG PET/CT are valuable tools, they must be interpreted alongside clinical and pathological findings. Researchers are also exploring biomarkers to further personalize treatment strategies for melanoma patients.
How Might This Impact Future Treatment Protocols?
If corroborated by larger studies, the integration of FDG PET/CT into standard monitoring protocols could reduce the need for repeat biopsies and enable more dynamic treatment adjustments. For patients with low-risk melanoma, this could mean fewer invasive procedures and more targeted care.
The case also highlights the growing interest in combining radiation therapy with immunotherapy, a strategy being tested in multiple cancer types. As Dr. James Chen, a radiation oncologist at Johns Hopkins, stated, “The intersection of precision radiation and immunology is one of the most exciting areas in oncology today. Tools like FDG PET/CT will be critical in optimizing these approaches.”
Related reading